Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin | Zendy

David R. Snydman | Zendy; L. A. McDermott | Zendy; Cheleste M. Thorpe | Zendy; Justin Chang | Zendy; Jenna Wick | Zendy; Seth T. Walk | Zendy; Richard Vickers | Zendy

Open Access

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

Author(s) -

David R. Snydman,

L. A. McDermott,

Cheleste M. Thorpe,

Justin Chang,

Jenna Wick,

Seth T. Walk,

Richard Vickers

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky135

Subject(s) - clostridium difficile , vancomycin , microbiology and biotechnology , agar dilution , biology , antimicrobial , ribotyping , clostridium difficile toxin a , antibiotics , medicine , minimum inhibitory concentration , bacteria , staphylococcus aureus , polymerase chain reaction , gene , biochemistry , genetics

We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridinilazole, a novel targeted-spectrum agent for treatment of C. difficile infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research